WO2021257027A1 - Composition efficace pour la cicatrisation de plaies - Google Patents

Composition efficace pour la cicatrisation de plaies Download PDF

Info

Publication number
WO2021257027A1
WO2021257027A1 PCT/TR2021/050540 TR2021050540W WO2021257027A1 WO 2021257027 A1 WO2021257027 A1 WO 2021257027A1 TR 2021050540 W TR2021050540 W TR 2021050540W WO 2021257027 A1 WO2021257027 A1 WO 2021257027A1
Authority
WO
WIPO (PCT)
Prior art keywords
grams
oil
composition according
composition
beeswax
Prior art date
Application number
PCT/TR2021/050540
Other languages
English (en)
Inventor
Ramin GHATARI
Shanli MOTIEI
Original Assignee
T.C. Istanbul Aydin Univeristesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T.C. Istanbul Aydin Univeristesi filed Critical T.C. Istanbul Aydin Univeristesi
Publication of WO2021257027A1 publication Critical patent/WO2021257027A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the invention relates to an effective composition in healing wounds caused by skin crevices and various burns.
  • EP2705847A1 in the literature A dermal composition for treating or soothing psoriasis lesions, wherein the composition comprises a tar extract, a corticosteroid, an antipruritic, an antibiotic, urea, an absorption base, water, lanolin, and propylene glycol.
  • the composition is a night cream comprising urea (100 g), saponified coal tar (70 ml), tolnaftate (20g ), aqueous (70 %) ammonium lactate (100 ml), clobetasol dipropionate (5 g), chlorpheniramine maleate (6 g), propylene glycol (50 ml), lanolin (30 g), sweet almond oil (50 ml), neo-pcl o/w (175 g), glycerine (50 g), and aqua conservans (distilled water containing parabens: 0.1% sodium nipagin and 0.05% sodium nipasol) to 1000 g.
  • a day cream comprising 500 g of an aqueous solution of hyaluronic acid (2 vol%), comprising 10 vol% propylene glycol, vitamin E (a-tocopherol; 10 g), sweet almond oil (50 g), argan oil (50 g), macadamia oil (50 g), peach essence (a drop) and neo-pcl o/w to 1000 g.” statements are included.
  • compositions used in the treatment of psoriasis which is a skin disease
  • the invention relates to a composition, in particular in the form of a cream, ointment, balm or gel, for the topical treatment of the skin, including, in a physiologically acceptable medium: 1.0-50 wt % of argan oil, and 0.05-2.5 wt % of hyaluronic acid, the latter being present optionally in the form of a physiologically acceptable salt, and having a molecular weight of 400 kDa.
  • the composition is used for the treatment of cutaneous injuries or cutaneous irritation.” statements are included.
  • composition based on argan oil and hyaluronic acid is disclosed for use in wound treatments.
  • the invention is generally based on a mixture of beeswax, olive oil and alkanna tinctoria, used in the treatment of wounds, especially 2nd degree burn wounds, preventing the wound care material from sticking to the injured tissue during dressing in the treatment of injured tissue. It is related to the wound care composition that reduces the pain in dressing changes, accelerates the wound treatment process and protects the wound against infections statements are included.
  • a composition used in the treatment of wounds, in particular burns is disclosed.
  • the aim of the invention is to provide a composition effective in healing wounds that overcomes the present disadvantages.
  • Another aim of the invention is to produce a completely natural and organic product.
  • Another aim of the invention is to present a composition that heals and destroys the wounds caused by burns on the skin without leaving any traces.
  • Another aim of the invention is to present a product with a shorter treatment time than chemical drugs.
  • Another aim of the invention is to produce a product that is free from the side effects caused by chemical substances.
  • Another aim of the invention is to present a product with low production cost and easy production steps.
  • the invention is an effective composition in healing wounds caused by clefts and various burns on the skin, characterized in that the said composition comprises 400 - 620 grams of beeswax, 264 - 412 grams of turmeric, 500 - 1000 grams of butter, 60 - 86 grams of argan oil, 2-15 grams of pomegranate seed oil, 9 - 22 grams of manuka oil, 50 - 65 grams of sesame oil.
  • Composition subject to the invention consists of 400-620 grams of beeswax, 264-412 grams of turmeric, 500-1000 grams of butter, 60-86 grams of argan oil, 2-15 grams of pomegranate seed oil, 9-22 grams of manuka oil, 50-65 grams of sesame oil, 2 -15 grams of avocado oil, 20-40 grams of sage oil and 2-15 grams of coconut oil.
  • the invention is an effective composition production method in healing wounds caused by skin clefts and various burns, characterized in that comprises the method steps of putting butter in a sterile container and melting it in a temperature environment of 80 degrees, after the butter melts, waiting 15-20 minutes, adding beeswax, mixing well after the butter and beeswax melt, and keeping it aside to reach 55 degrees, adding turmeric and beeswax well, then adding argan oil, pomegranate seed oil, manuka oil and sesame oil in order to cooling and mixing from liquid to solid.
  • the oil in butter helps the skin to be smooth and soft. It prevents the wound from drying out and reduces inflammation.
  • Beeswax is produced naturally by various bee species. Almost everything from vitamin A to antioxidants, which is necessary to have a lively and healthy skin, is present in beeswax.
  • Turmeric increases its antioxidant effect on small blood vessels such as capillaries and has a positive effect on collagen and skin tissue.
  • turmeric is an antibacterial and antifungal agent.
  • Argan oil is rich in fatty acids such as linoleic acid, which contains vitamin E.
  • This oil is a natural antioxidant and can increase intracellular oxygen delivery.
  • Antioxidant compounds tocopherols, phenols, carotenoids
  • the antioxidants in it eliminate free radicals and make the skin glow.
  • butter is put in a sterile container and melted in a temperature of 80 degrees, and after it melts, beeswax is added after waiting for 15-20 minutes.
  • Said beeswax is expected to melt at the same temperature. After the oil and beeswax melt, care should be taken to mix them well.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition efficace pour la cicatrisation de plaies provoquées par des crevasses cutanées et diverses brûlures.
PCT/TR2021/050540 2020-06-17 2021-06-05 Composition efficace pour la cicatrisation de plaies WO2021257027A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/09361 2020-06-17
TR2020/09361A TR202009361A2 (tr) 2020-06-17 2020-06-17 Yara i̇yi̇leşti̇rmede etki̇li̇ bi̇r kompozi̇syon

Publications (1)

Publication Number Publication Date
WO2021257027A1 true WO2021257027A1 (fr) 2021-12-23

Family

ID=75470185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050540 WO2021257027A1 (fr) 2020-06-17 2021-06-05 Composition efficace pour la cicatrisation de plaies

Country Status (2)

Country Link
TR (1) TR202009361A2 (fr)
WO (1) WO2021257027A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077422A (zh) * 2023-01-04 2023-05-09 成都大学 一种石榴籽油甘油二酯纳米乳凝胶剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080063916A (ko) * 2007-01-03 2008-07-08 주식회사 엘지생활건강 아유르베다 밸런싱테러피 효과를 갖는 화장료 조성물
CN103610631A (zh) * 2013-12-13 2014-03-05 王爱丽 一种护手霜的制备方法
CN105030584A (zh) * 2015-07-03 2015-11-11 北京枫华草木洗涤用品有限公司 纯天然防雾霾面霜
CN108904424A (zh) * 2018-03-21 2018-11-30 广州贵有日用品有限公司 具有修护作用的护唇口红
CN110452789A (zh) * 2019-08-29 2019-11-15 于泽浩 一种草本精油手工皂的成分及其制作方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080063916A (ko) * 2007-01-03 2008-07-08 주식회사 엘지생활건강 아유르베다 밸런싱테러피 효과를 갖는 화장료 조성물
CN103610631A (zh) * 2013-12-13 2014-03-05 王爱丽 一种护手霜的制备方法
CN105030584A (zh) * 2015-07-03 2015-11-11 北京枫华草木洗涤用品有限公司 纯天然防雾霾面霜
CN108904424A (zh) * 2018-03-21 2018-11-30 广州贵有日用品有限公司 具有修护作用的护唇口红
CN110452789A (zh) * 2019-08-29 2019-11-15 于泽浩 一种草本精油手工皂的成分及其制作方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077422A (zh) * 2023-01-04 2023-05-09 成都大学 一种石榴籽油甘油二酯纳米乳凝胶剂
CN116077422B (zh) * 2023-01-04 2024-02-13 成都大学 一种石榴籽油甘油二酯纳米乳凝胶剂

Also Published As

Publication number Publication date
TR202009361A2 (tr) 2020-07-21

Similar Documents

Publication Publication Date Title
US6780439B2 (en) Wound treatment solution and method for using same
CA2891602C (fr) Composition renfermant un orthosilicate et son utilisation en vue de la regeneration de tissus
US20040121020A1 (en) Composition
US20030104018A1 (en) Skin product having micro-spheres, and processes for the production thereof
JP2024059876A (ja) 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物
WO2014190179A2 (fr) Gel d'urée-silicone pour cicatrices et traitement d'hydratation, et procédé pour l'utiliser
US10426803B2 (en) Topical medicament for skin and mucosal injuries
US7141252B2 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
WO2021257027A1 (fr) Composition efficace pour la cicatrisation de plaies
US20140348873A1 (en) Urea-Silicone Gel for Hyperkeratosis Treatment
US20230390176A1 (en) Cosmetic Skin and Medical Cream
CA2994177C (fr) Composition d'emollient comprenant de l'huile d'emeu et de l'huile de jojoba, et utilisations connexes
CN101642575A (zh) 软膏状药用基质
US20080193552A1 (en) Topical medicament for skin injuries and disorders
TW201632191A (zh) 一種用於促進傷口癒合或預防、減少傷口疤痕生成的醫藥組合物
RU2803777C1 (ru) Восковая мазь "ВОСКОСАП"
KR101607229B1 (ko) 말기름을 함유하는 상처 치료용 조성물
RU2682454C1 (ru) Мазь для лечения термических ожогов и способ их лечения
KR100289906B1 (ko) 피부용조성물
JP2024516248A (ja) 創傷治療組成物
RU2148397C1 (ru) Мазь для лечения заболеваний и повреждений кожи
CN116785229A (zh) 一种伤口护理软膏及其制备方法
WO2006061446A1 (fr) Compositions pharmaceutiques
EA006948B1 (ru) Состав для лечения кожных заболеваний
RO128266B1 (ro) Unguent cicatrizant cu extract de calendula officinalis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21825694

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21825694

Country of ref document: EP

Kind code of ref document: A1